Response to combined molecular targeting: defining the role of P-STAT3.
Src family kinase (SFK)-targeting agents are currently undergoing clinical investigation for treatment of solid malignancies. Epidermal growth factor receptor (EGFR)-independent phosphorylation of STAT3 (P-STAT3) has been identified as a mechanism of tumor resistance to agents targeting SFK. Tumor P-STAT3 levels may be an important indicator of EGFR- and SKF-targeted antitumor treatment efficacy.
Department of Otolaryngology and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ann Marie
AM
Egloff
Jennifer R
JR
Grandis
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002986:Clinical Trials as Topic; D000069439:Dasatinib; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D058990:Molecular Targeted Therapy; D010190:Pancreatic Neoplasms / Q000178:diet therapy* / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D050796:STAT3 Transcription Factor / Q000378:metabolism*; D013844:Thiazoles / Q000008:administration & dosage; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011799:Quinazolines; D050796:STAT3 Transcription Factor; D013844:Thiazoles; D003841:Deoxycytidine; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D000069439:Dasatinib; D000093542:Gemcitabine
Cancer. 2007 Apr 15;109(8):1561-9
17354229
Cancer. 2010 Dec 15;116(24):5599-607
20824720
J Clin Oncol. 2010 Oct 20;28(30):4609-15
20855820
Nat Chem Biol. 2010 Apr;6(4):291-9
20190765
Cancer Res. 2009 Mar 1;69(5):1958-65
19223541
Clin Cancer Res. 2009 Nov 15;15(22):6852-61
19861436
J Clin Oncol. 2010 Mar 10;28(8):1387-94
20142592
Mol Cancer Ther. 2010 Aug;9(8):2322-32
20682659
Clin Cancer Res. 2011 Feb 1;17(3):483-93
21266529
J Oncol. 2009;2009:896407
19636423
Science. 2008 Sep 26;321(5897):1801-6
18772397